---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report. Covers Cost-effectiveness evidence and Budget impact model. 29 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: absence of vonaprument economic evaluations and comparator cost-effectiveness evidence

No cost-effectiveness analysis, budget impact model, health technology assessment, or price of vonaprument (ANX007) was identified. ARCHER II, the phase 3 trial of monthly vonaprument 5.0 mg per eye versus sham in 659 participants, had a Data Monitoring Committee assessment of its Month 15 primary endpoint scheduled for the fourth quarter of 2026, so no product-specific efficacy input for a model was available. The manufacturer states that there is no assurance a product will be considered “cost-effective by third-party payors”. The comparator evidence consists of analyses of the two complement inhibitors approved in the United States, pegcetacoplan and avacincaptad pegol.

Two U.S. cost analyses based on 2022 Medicare reimbursement, estimated 2-year treatment costs of $70,000 (every month) and $34,600 (every other month) for pegcetacoplan, with modeled costs per QALY gained of $706,000 and $397,000, and 2-year costs of $67,400 (every month) and $40,600 (every other month) for avacincaptad pegol. For extrafoveal GA, the cost per mm2 of retinal pigment epithelium saved was higher with avacincaptad pegol than with pegcetacoplan for both dosing regimens ($119,000 vs $54,000 every month; $57,100 vs $31,400 every other month). A U.S. cost-utility model with authors from Apellis Pharmaceuticals, which included the costs and utility loss of informal caregiving, reported $77,735 per QALY gained over a lifetime horizon, and $55,806 per QALY gained for lesions at least 250 μm from the foveal center.

The Australian Pharmaceutical Benefits Advisory Committee (PBAC) assessed submissions for pegcetacoplan (November 2025) and avacincaptad pegol (March 2026). Each submission was a cost-utility analysis versus best supportive care with a 20-year time horizon; the pegcetacoplan model defined health states by ETDRS letter bands, and the avacincaptad pegol model by GA lesion size. For both products the PBAC stated that a price reduction would be required to achieve cost-effectiveness, and considered an ICER in the order of $55,000 to < $75,000 (pegcetacoplan) and $45,000 to < $55,000 (avacincaptad pegol) per QALY gained acceptable. For pegcetacoplan, the PBAC considered it reasonable to accept the financial estimates as the basis of a risk sharing arrangement. Should pegcetacoplan proceed to listing, the PBAC advised a cost-minimisation approach so that avacincaptad pegol was no more costly than pegcetacoplan. The NICE appraisal of pegcetacoplan was suspended after information the company provided in February 2025, which stated that it had not received MHRA marketing authorisation for the indication, and has since been discontinued.

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm); [Patel et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37572871/); [Patel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38777140/); [Cummings Joyner et al. (2023)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3788/133629); [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3); [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3); [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

<a id="topic-4.1-2"></a>

#### Manufacturer statement on payer assessment of cost-effectiveness

> “Furthermore, there can be no assurance that a product will be considered medically reasonable and necessary for a specific indication, that a product will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payor’s reimbursement policies will not adversely affect the ability to sell a product profitably.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-4.1-3"></a>

#### Pegcetacoplan cost-effectiveness analysis: U.S. Medicare costs and cost per QALY

> “Costs were based on 2022 Medicare reimbursement data. Specific outcomes were extrapolated from the DERBY and OAKS trials. Assumptions were made for the lifetime analysis based on a theoretical logistic growth model of the atrophy.”
> “The costs to treat GA in every month (EM) and every-other-month (EOM) treatment groups over the 2 years as reported were $70 000 and $34 600, respectively.”
> “The modeled lifetime costs were $350 000 (EM) and $172 000 (EOM), or $309 000/mm2 (EM) and $180 000 (EOM) /mm2.”
> “The costs/quality-adjusted life-year gained based on modeled visual loss with 95% atrophy were $706 000 (EM) and $397 000 (EOM).”
> “Treatment of GA with intravitreal pegcetacoplan EOM was more cost effective than EM.”

Source: [Patel et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37572871/)

<a id="topic-4.1-4"></a>

#### Avacincaptad pegol cost-effectiveness analysis: comparison with pegcetacoplan

> “Costs were based on 2022 Medicare reimbursement data for both facility (hospital-based) and nonfacility settings in Miami.”
> “The cost to treat GA with ACP in EM and EOM treatment groups over the 2 years as reported was $67 400 and $40 600, respectively.”
> “The (facility-based) costs per unit area of retinal pigment epithelium saved for patients with extrafoveal GA over the 2-year period were $119 000/mm2 (EM ACP) versus $54 000/mm2 (EM PEG) (P < 0.001), $57 100/mm2 (EOM ACP) versus $31 400/mm2 (EOM PEG) (P < 0.001), and $45 300/mm2 (hypothetical EOM from outset ACP).”
> “When assessing extrafoveal lesions, ACP was less cost effective than PEG for both EM and EOM treatment.”

Source: [Patel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38777140/)

<a id="topic-4.1-5"></a>

#### Pegcetacoplan de novo U.S. cost-utility model including informal caregiving

> “We developed a de novo cost-utility model for evaluating the treatment of GA and the impact of delaying vision loss.”
> “This is a health-state transition model with health states defined by best corrected visual acuity (BCVA) bands measured by Early Treatment for Diabetic Retinopathy Study (ETDRS) letters.”
> “When incorporating the costs and utility loss of informal caregiving for those with severe or total vision loss, the incremental cost per quality-adjusted life year (QALY) gained following treatment with pegcetacoplan is $77,735 assuming a lifetime model with costs and benefits discounted at 3.5%.”
> “Similarly, treating GA before the fovea is encroached, defined as GA with lesions at least 250 μm from the foveal center, carries an incremental cost of just $55,806 per QALY gained.”

Source: [Cummings Joyner et al. (2023)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3788/133629)

<a id="topic-4.1-6"></a>

#### Australian PBAC assessment of pegcetacoplan: model structure and ICER

> “Listing was requested on the basis of a cost-utility analysis (CUA) versus best supportive care (BSC).”
> “20 years (versus 24 month follow up in the DERBY and OAKS trials).”
> “Defined by number of ETDRS letters: ≥ 76, 75-66, 65-51, 50-36 and ≤ 35 letters and dead.”
> “The PBAC noted that multivariate analyses that incorporated each of these inputs increased the base case ICER from $45,000 to < $55,000 per QALY gained to $95,000 to < $115,000 per QALY gained.”
> “The PBAC considered the cost-effectiveness analysis would be more reliable with these alternative parameters and an incremental cost-effectiveness ratio (ICER) in the order of $55,000 to < $75,000 per QALY gained would be acceptable. A price reduction would be required to achieve cost-effectiveness based on the revised model.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="topic-4.1-7"></a>

#### Australian PBAC assessment of avacincaptad pegol: model structure, ICER, and cost-minimisation with pegcetacoplan

> “Listing was requested on the basis of a cost-utility analysis versus best supportive care (BSC).”
> “20 years (versus 18 months follow up in GATHER1)”
> “Defined by GA lesion size”
> “are proxies for disease severity and risk of vision loss but do not directly measure functional vision or visual acuity”
> “The ESC noted that this multivariate analysis increased the base case ICER from $55,000 to < $75,000 per QALY gained to $115,000 to < $135,000 per QALY gained.”
> “In this context the PBAC considered an ICER in the order of $45,000 to < $55,000 per QALY gained would be acceptable. The PBAC noted that a price reduction would be required to achieve cost effectiveness.”
> “Should pegcetacoplan proceed to PBS listing, the PBAC advised that a cost-minimisation approach (accounting for differences in administration costs) was appropriate to ensure that ACP was no more costly than pegcetacoplan.”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="topic-4.1-8"></a>

#### NICE appraisal of pegcetacoplan: suspension and discontinuation

> “Please note that following on from information provided to NICE by the company in February 2025, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.”
> “For information, the company have advised that they did not receive Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication. Therefore, NICE has decided to suspend this appraisal from its current work programme.”

Source: [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

<a id="topic-4.2.1-1"></a>

##### Budget impact model of vonaprument

No evidence found.

<a id="topic-4.2.1-2"></a>

##### Pegcetacoplan PBAC financial estimates: epidemiological approach

> “The submission used an epidemiological approach to estimate the number of prevalent patients who would be eligible for the proposed pegcetacoplan treatment.”
> “As there is currently no treatment for GA, this approach is appropriate.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="topic-4.2.1-3"></a>

##### Avacincaptad pegol PBAC financial estimates: epidemiological approach and market share

> “An epidemiological approach was used to estimate the extent of use and financial implications of listing ACP on the PBS.”
> “The evaluation considered this was a reasonable approach given that there is currently no active comparator listed on the PBS. However, if pegcetacoplan is listed, market share calculations to all future projections of uptake and expenditure would be necessary.”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

<a id="topic-4.2.2-1"></a>

##### Budget impact model of vonaprument: perspective and time frame

No evidence found.

<a id="topic-4.2.2-2"></a>

##### Pegcetacoplan PBAC financial estimates: payer perspective and 6-year horizon

> “The total cost to the PBS/RPBS of listing pegcetacoplan was estimated to be $50 million to < $60 million in Year 6, and a total of $200 million to < $300 million in the first 6 years of listing.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="topic-4.2.2-3"></a>

##### Avacincaptad pegol PBAC financial estimates: population projections, 2027 to 2032

> “ABS population projections, 2027-2032 (base year 2022) for individuals aged ≥ 50 years old.”
> “Net cost to PBS/RPBS/MBS”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

##### Budget impact model of vonaprument: eligible population

No evidence found.

<a id="topic-4.2.3-2"></a>

##### Company estimate of the U.S. treated and diagnosed GA population

> “Based on market reports, approximately 75,000 patients are being actively treated with available therapies in the US, representing ~10% of the 800,000 people diagnosed with GA/under the care of retina specialists, but only about 5% of the 1.5M US population with GA”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-4.2.3-3"></a>

##### Company estimate of GA prevalence in the United States and worldwide

> “GA affects more than an estimated one million people in the United States and eight million people worldwide”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-4.2.3-4"></a>

##### Pegcetacoplan PBAC financial estimates: prevalence, eligibility, and uptake inputs

> “Prevalence of 1.29% (patients aged 60 years and older) based on late AMD and the proportion of patients with GA as reported in Australian National Eye Health Survey (NEHS).”
> “Proportion of patients with bilateral GA – 63.5% (IRIS) and proportion of patients with non-subfoveal GA in one eye and subfoveal GA in the fellow eye 33.9% (FRB!)”
> “The uptake rate was based on the uptake of ranibizumab in its first five full years of listing (2008-2012), adjusted to account for differences in annual injection rates.”
> “DUSC considered that there may be “warehoused” patients specifically waiting for this drug to become available on the PBS.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="topic-4.2.3-5"></a>

##### Avacincaptad pegol PBAC financial estimates: incidence, prevalence, and non-subfoveal proportion

> “0.17%, calculated from the cumulative 10-year incidence rate of 1.7% for GA reported in Wang et. al”
> “0.52%, weighted prevalence rate based on the prevalence rates reported for non-indigenous (aged ≥ 50 years old) and indigenous Australians (aged ≥ 40 years old) in Keel et. al”
> “31.60%, based on a retrospective analysis of patients in the IRIS registry with less than 24 months of follow-up data”
> “Prevalent patients were included in year 1 only.”
> “The prevalence rate for non-indigenous Australians when patients aged < 50 years old are excluded was 0.26% (compared to 0.17%).”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

##### Price of vonaprument

No evidence found.

<a id="topic-4.2.4-2"></a>

##### Vonaprument dose and frequency in ARCHER II

> “Vonaprument (ANX007) Monthly”
> “5.0 mg/eye”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-4.2.4-3"></a>

##### Medicare Part B payment limits for comparator complement inhibitors, October to December 2026

| HCPCS code and product | Short description | Billing unit | Payment limit per billing unit (dollars) | Notes |
| --- | --- | --- | --- | --- |
| J2781 pegcetacoplan (Syfovre) | “Inj, pegcetacoplan, 1mg” | “1 MG” | “135.267” | “AMP-based payment limit” |
| J2782 avacincaptad pegol (Izervay) | “Inj avacincaptad pegol 0.1mg” | “0.1 MG” | “100.563” | Not reported |

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.2.4-4"></a>

##### Medicare Part B spending and beneficiaries for comparator complement inhibitors, 2023 and 2024

| HCPCS code and product | Total spending, 2023 (dollars) | Total beneficiaries, 2023 | Total spending, 2024 (dollars) | Total claims, 2024 | Total beneficiaries, 2024 | Average spending per claim, 2024 (dollars) | Average spending per beneficiary, 2024 (dollars) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| J2781 pegcetacoplan (Syfovre) | “76651580.03” | “17414” | “403855394.8” | “148576” | “29338” | “2718.173829” | “13765.60757” |
| J2782 avacincaptad pegol (Izervay) | Not reported | Not reported | “190365232.8” | “73172” | “18308” | “2601.613086” | “10397.92619” |

Source: [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/76a714ad-3a2c-43ac-b76d-9dadf8f7d890/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

<a id="topic-4.2.4-5"></a>

##### Medicare Part B quarterly spending and beneficiaries for comparator complement inhibitors, 2025 and first quarter of 2026

| HCPCS code and product | Period | Total spending (dollars) | Total claims | Total beneficiaries | Average spending per claim (dollars) | Average spending per beneficiary (dollars) |
| --- | --- | --- | --- | --- | --- | --- |
| J2781 pegcetacoplan (Syfovre) | “2025 (Q1-Q4)” | “451069360.05” | “168366” | “32021” | “2679.1000561” | “14086.673122” |
| J2781 pegcetacoplan (Syfovre) | “2026 (Q1)” | “109568082.68” | “41654” | “24179” | “2630.4336361” | “4531.5390496” |
| J2782 avacincaptad pegol (Izervay) | “2025 (Q1-Q4)” | “364934587.1” | “140741” | “27497” | “2592.9515003” | “13271.796454” |
| J2782 avacincaptad pegol (Izervay) | “2026 (Q1)” | “105232261.84” | “41264” | “23315” | “2550.2196064” | “4513.5004006” |

Source: [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

<a id="topic-4.2.4-6"></a>

##### Launch wholesale acquisition costs of comparator complement inhibitors, 2023

> “Astellas set the drug’s list price at $2,100 per vial, the spokesperson said. That’s slightly less than the $2,190-per-vial cost Apellis set for Syfovre at launch.”

Source: [Fidler (2023)](https://www.biopharmadive.com/news/astellas-iveric-fda-approval-geographic-atrophy-izervay/690052/)

<a id="topic-4.2.4-7"></a>

##### Medicare payment for intravitreal injection (CPT 67028), 2025 and 2026

| CPT code | 2025 non-facility total RVUs | 2026 non-facility total RVUs | 2025 non-facility pay (dollars) | 2026 non-facility pay (dollars) | Change in non-facility pay, 2025 to 2026 |
| --- | --- | --- | --- | --- | --- |
| “67028” | “3.37” | “3.42” | “$109.01” | “$114.23” | “4.79%” |

Source: [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf)

<a id="topic-4.2.4-8"></a>

##### Comparator dosing frequency assumed in PBAC financial estimates

> “4.71 injections per year, calculated from the totals at 24 months for the OAK and DERBY trials and adjusted for compliance (95.5%) to derive 4.5 injections per year.”
> “The PBAC advised that the number of pegcetacoplan scripts per year should be revised to reflect treatment compliance reported in the key trials (i.e. 5.39 scripts per year).”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

> “As such, the submission estimated that patients would require 12 scripts per year for initial treatment and 6 scripts per year for continuing treatment.”
> “A mean treatment duration of 24.99 months (derived from the modelled TTD) was applied to all eligible patients that elect treatment.”
> “Costs for the intravitreal administration of ACP was included per script using MBS item 43030 ($350.85). This was reasonable.”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

<a id="topic-4.2.5-1"></a>

##### Budget impact model of vonaprument: outcomes

No evidence found.

<a id="topic-4.2.5-2"></a>

##### Avacincaptad pegol PBAC financial estimates: outcomes reported

> “Number of patients treated”
> “Patient-years on treatment”
> “Number of scripts dispensed”
> “Net cost to PBS/RPBS”
> “Net cost to MBS”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

<a id="topic-4.2.6.1-1"></a>

###### Budget impact model of vonaprument: base case

No evidence found.

<a id="topic-4.2.6.1-2"></a>

###### Pegcetacoplan PBAC financial estimates: base case

> “The total cost to the PBS/RPBS of listing pegcetacoplan was estimated to be $50 million to < $60 million in Year 6, and a total of $200 million to < $300 million in the first 6 years of listing.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="topic-4.2.6.1-3"></a>

###### Avacincaptad pegol PBAC financial estimates: base case

> “The submission estimated a cost of $20 million to < $30 million in year 1, increasing to $60 million to < $70 million in year 6 and a cumulative cost of $300 million to < $400 million over the first 6 years of listing.”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

<a id="topic-4.2.6.2-1"></a>

###### Budget impact model of vonaprument: scenario analyses

No evidence found.

<a id="topic-4.2.6.2-2"></a>

###### Avacincaptad pegol PBAC financial estimates: continued monthly dosing after year 1

> “Scenario 1: 50% of patients continue EM dosing after year 1”
> “Scenario 2: 100% of patients continue EM dosing after year 1”
> “The ESC noted that while the estimated cost to the PBS/RPBS remained the same in year 1 ($20 million to < $30 million), the estimated cost increased to $70 million to < $80 million in year 6 with a cumulative cost of $300 million to < $400 million over the first 6 years of listing.”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="topic-4.2.6.2-3"></a>

###### Pegcetacoplan PBAC financial estimates: revisions to scripts and uptake

> “The PBAC agreed with the DUSC that the number of pegcetacoplan scripts per year was underestimated.”
> “The PBAC considered that, with these amendments and with the price reduction required to achieve cost effectiveness outlined in paragraph 7.15, it would be reasonable to accept the financial estimates as the basis of a risk sharing arrangement.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

##### Summary: inputs a vonaprument budget impact model would require

No budget impact model of vonaprument exists. A U.S. payer model would require four inputs that are not yet available: a price (none announced), efficacy and discontinuation data from ARCHER II, the labeled dosing frequency (ARCHER II tests monthly vonaprument 5.0 mg per eye), and the eligible population defined by an approved indication.

Comparator inputs exist for the two complement inhibitors already approved in the United States. October to December 2026 Medicare Part B payment limits were $135.267 per 1 mg of pegcetacoplan (J2781, an AMP-based payment limit) and $100.563 per 0.1 mg of avacincaptad pegol (J2782); launch list prices in 2023 were $2,190 and $2,100 per vial. Medicare Part B spending in 2025 was $451.1 million for Syfovre (32,021 beneficiaries; $2,679 per claim) and $364.9 million for Izervay (27,497 beneficiaries; $2,593 per claim), compared with $403.9 million (29,338 beneficiaries) and $190.4 million (18,308 beneficiaries) in 2024. The 2026 national non-facility Medicare payment for an intravitreal injection (CPT 67028) was $114.23. The manufacturer estimates that approximately 75,000 U.S. patients are actively treated with available therapies, about 10% of the 800,000 diagnosed with GA or under the care of retina specialists and about 5% of an estimated 1.5 million U.S. patients with GA.

The two Australian PBAC financial estimates illustrate the structure such a model would take: an epidemiological approach, a prevalence of 1.29% (pegcetacoplan, aged 60 years and older) or 0.52% (avacincaptad pegol, aged 50 years and older), the proportion with non-subfoveal GA (31.60% for avacincaptad pegol), an uptake curve, injections per year, and administration costs, over 6 years. Both estimates were sensitive to dosing frequency: the PBAC revised pegcetacoplan from 4.5 to 5.39 scripts per year, and for avacincaptad pegol the evaluation tested scenarios in which 50% or 100% of patients continued monthly dosing after year 1, after which the estimated year 6 cost was $70 million to < $80 million, compared with $60 million to < $70 million in the submission. The evaluation of avacincaptad pegol stated that market share calculations would be necessary if pegcetacoplan were listed, a consideration that would also apply to a third agent.

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip); [Fidler (2023)](https://www.biopharmadive.com/news/astellas-iveric-fda-approval-geographic-atrophy-izervay/690052/); [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/76a714ad-3a2c-43ac-b76d-9dadf8f7d890/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782); [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782); [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf); [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3); [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
